For decades, pharmacy benefit managers, or PBMs, have operated largely behind the scenes, controlling drug prices and shaping healthcare benefits in ways most patients and even employers barely notice. In 2026, however, the curtain is finally being pulled back. The Big Three—Express Scripts, CVS Caremark, and OptumRx—are facing unprecedented scrutiny as both federal and state governments move to hold them accountable. From transparency rules to new restrictions on rebate practices, the industry is at a crossroads, and the consequences will ripple through patients, pharmacies, and employers alike.

Earlier this year, Congress included landmark PBM reform provisions in the Consolidated Appropriations Act. “This is the most significant federal intervention in PBM practices in decades,” says a healthcare policy analyst familiar with the legislation. Under the new rules, PBM compensation can no longer be tied to drug prices or hidden rebates. Instead, pay must reflect bona fide service fees, and all rebates in Medicare Part D must flow directly back to employers’ health plans. Spread pricing in Medicaid, the practice that allows PBMs to profit from the difference between what they pay pharmacies and what they charge plans, is now banned, replaced with a full pass-through model. These changes are designed to shine a light on the opaque mechanisms that critics say have inflated drug costs for years.

The spotlight intensified when the Federal Trade Commission reached a settlement with Express Scripts over alleged practices that inflated insulin prices. Under the agreement, members’ out-of-pocket costs must be calculated based on net prices rather than inflated list prices, and low-cost options must count toward deductibles. Reporting to plan sponsors will become more detailed, providing a clearer picture of how rebates and fees actually flow. While similar actions against CVS Caremark and OptumRx are still pending, the move signals that the federal government is serious about holding PBMs accountable. At the same time, the Department of Labor proposed a rule requiring PBMs to disclose all fees and compensation to fiduciaries of employer-sponsored health plans. Transparency, long promised but rarely enforced, is now becoming a legal requirement.

States are also stepping into the ring, often with more aggressive tactics than the federal government. Arkansas made headlines with a law attempting to ban PBM ownership of pharmacies, a move designed to eliminate conflicts of interest and give independent pharmacies a fighting chance. However, the law was blocked by a federal judge, citing likely violations of the Commerce Clause and ERISA preemption. Other states have pressed forward, undeterred. California and Colorado have enacted rules requiring full disclosure of PBM compensation and rebate pass-through, Massachusetts has expanded PBM licensing requirements, and Utah has outlawed spread pricing entirely. “States are becoming the testing grounds for real PBM reform,” says a benefits consultant with experience in multi-state employer plans.

The stakes are high. Employers are pushing for reforms that could lower costs for their members, patients are demanding clarity in pricing, and independent pharmacies are seeking protection against the market dominance of the Big Three. Critics argue that PBMs’ opaque practices have long inflated drug costs, while supporters claim the industry’s complex rebate system reduces net costs for some plans. With federal and state actions converging, the debate is now out in the open, and the industry can no longer operate in the shadows. Looking ahead, transparency will be the cornerstone of PBM reform. Legal battles over vertical integration and PBM-owned pharmacies will likely set the precedent for what states can achieve in regulating the industry. Employers and patients should watch for changes in plan design, pharmacy participation, and drug pricing. As one healthcare policy expert notes, “2026 could be the year that fundamentally reshapes how PBMs operate and how Americans experience their prescription drug benefits.”

The PBM industry, once invisible, is now under the brightest scrutiny it has ever faced. How the Big Three respond, and how federal and state regulators continue to push for reform, will define the landscape for years to come. For patients, employers, and pharmacies, the coming months may finally bring the clarity and fairness long promised but rarely delivered.